1097-0215/asset/cover.gif?v=1&s=9bea5e55449dab2cff7ad3b06277cc9745417a23 "International Journal of Cancer")
Fax: +32-2-359-03-59
1097-0215/asset/olbannerleft.jpg?v=1&s=45719cd7de57873027993264fcc568b335a8cd56)
1097-0215/asset/olbannerright.jpg?v=1&s=5e0fba63c1309b3036eb9215a0e1e83dd02efd19)
Cancer Diagnosis and Therapy
You have full text access to this OnlineOpen article
Efficient tumor targeting by single-domain antibody fragments of camels
Article first published online: 14 JAN 2002
DOI: 10.1002/ijc.10212
Copyright © 2002 Wiley-Liss, Inc.
Additional Information
How to Cite
Cortez-Retamozo, V., Lauwereys, M., Hassanzadeh Gh., G., Gobert, M., Conrath, K., Muyldermans, S., De Baetselier, P. and Revets, H. (2002), Efficient tumor targeting by single-domain antibody fragments of camels. Int. J. Cancer, 98: 456–462. doi: 10.1002/ijc.10212
Publication History
- Issue published online: 28 FEB 2002
- Article first published online: 14 JAN 2002
- Manuscript Accepted: 5 NOV 2001
- Manuscript Revised: 15 OCT 2001
- Manuscript Received: 2 JUL 2001
Funded by
- Fonds Voor Wetenschappelijk Onderzoek (FWO). Grant Number: G. 046399
- Vrije Universiteit Brussel (VUB) (Concerted Actions)
- Instituut Voor de Aanmoediging Van Innovatie Door Wetenschap en Technologie in Vlaanderen (IWT)
REFERENCES
- 1, , , et al. The development of monoclonal antibodies for the therapy of cancer. Crit Rev Eukaryot Gene Expr 1998;8: 321–45.
- 2. Recombinant antibody fragments. Curr Opin Biotechnol 1998;9: 395–402.
- 3, , , et al. Single-chain antigen-binding proteins. Science 1988;241: 423–6.
- 4. Recombinant antibody constructs in cancer therapy. Curr Opin Immunol 1999;11: 548–57.
- 5, , , et al. An improved linker for scFv with reduced aggregation and enhanced proteolytic stability. Protein Eng 1993;6: 989–93.
- 6, , , et al. Naturally occurring antibodies devoid of light chains. Nature 1993;363: 446–8.
- 7, , , et al. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett 1997;414: 521–6.
- 8, , , et al. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO J 1998;17: 3512–20.
- 9, , Unique single-domain antigen binding fragments derived from naturally occurring camel heavy-chain antibodies. J Mol Recognit 1999;12: 131–40.Direct Link:
- 10, . 1999. Single domain antibodies: comparison of camel VH and camelised human VH domains. J Immunol Methods 1999;231: 25–38.
- 11, . Redefining the minimal antigen-binding fragment. Nature Structural Biol 1996;3: 733–6.
- 12. Mix and match: building manifold binding sites. Nat Biotechnol 1997;15: 125–6.
- 13, , , et al. Camel single-domain antibodies as modular building units in bispecific and bivalent constructs. J Biol Chem 2001;276: 7346–7350.
- 14, , , et al. Experimental analysis of the metastatic phenotype of malignant leukocytes. Anti-Cancer Res 1991;11: 4–73.
- 15, . Characterization of 3LL-Tumor variants generated by in vitro macrophage-mediated selection. Int J Cancer 1987;39: 343–52.Direct Link:
- 16, , , et al. 1997. Comparison of llama VH sequences from conventional and heavy-chain antibodies. Mol Immunol 1997; 34: 1121–31.
- 17. Anatomy of the antibody molecule. Mol. Immunol 1994;31: 169–217.
- 18, , , et al. Human anti-(murine Ig) antibody responses in patients with hepatocellular carcinoma receiving intrahepatic arterial 131I-labeled Hepama-1 mAb. Preliminary results and discussion. Cancer Immunol. Immunother 1994;39: 332–6.
- 19, , , et al. Analysis of antiglobulin (HAMA) response in a group of patients with B-lymphocytic malignancies treated with 131I-Lym-1. Int J Biol Markers 1995;10: 67–74.
- 20, , , et al. The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A. Cancer Res 2000;60: 1921–6.
- 21, , , et al. Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16 bispecific antibody. Cancer Immunol Immunother 2000;49: 173–80.
- 22, , , et al. Isolation of picomolar affinity anti-c-erB2 single-chain Fv by molecular evolution of the complementarity determining regions in the centre of the antibody combining site. J Mol Biol 1996;263: 551–67.
- 23, , , et al. Binding activities of a repertoire of single immunoglobulin variable domains secreted from E. coli. Nature 1989;341: 544–6.
- 24, . 1994. Camelizing human antibody fragments: NMR studies on VH domains. FEBS Lett 1994;339: 285–90.
- 25, , , et al. 1994. Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Eng 1994;7: 1129–35.
- 26, , , et al. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J 1994;13: 3245–60.
- 27, , , et al. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 1996;14: 309–14.
- 28, , , et al. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J Biol Chem 1999;274: 18218–30.
- 29, , , et al. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res 1998a; 58: 485–90.
- 30, , , et al. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res 1999;59: 347–52.
- 31, , , et al. Prolonged in vivo tumor retention of a human diabody targeting the extracellular domain of human HER-2/neu. Br J Cancer 1998;77: 1405–12.
- 32, , , et al. Therapeutic effects of monoclonal antibody-β-lactamase conjugates in combination with a nitrogen mustard anticancer prodrug in models of human renal cell carcinoma. J Med Chem 1998;41: 1507–12.
- 33, , , et al. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res 2001;61: 4750–5.
- 34, , , et al. A modeling analysis of monoclonal antibody percolation through tumors: a binding site barrier. J Nucl Med 1990;31: 1191–8.
- 35, , , et al. 2000. Isolation of antigen-specific llama VHH antibody fragment and their high level secretion by Saccharomyces cerevisiae. J Biotechnol 2000;78: 11–21.